JP2020134179A - Non-destructive cell analysis method - Google Patents
Non-destructive cell analysis method Download PDFInfo
- Publication number
- JP2020134179A JP2020134179A JP2019024097A JP2019024097A JP2020134179A JP 2020134179 A JP2020134179 A JP 2020134179A JP 2019024097 A JP2019024097 A JP 2019024097A JP 2019024097 A JP2019024097 A JP 2019024097A JP 2020134179 A JP2020134179 A JP 2020134179A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- sugar chain
- cell
- analysis method
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004458 analytical method Methods 0.000 title claims abstract description 31
- 210000004027 cell Anatomy 0.000 claims abstract description 66
- 235000000346 sugar Nutrition 0.000 claims abstract description 40
- 238000002493 microarray Methods 0.000 claims abstract description 11
- 108091008324 binding proteins Proteins 0.000 claims abstract description 9
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract 2
- 239000002609 medium Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 230000005284 excitation Effects 0.000 claims description 9
- 239000012679 serum free medium Substances 0.000 claims description 5
- 108090000288 Glycoproteins Proteins 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 11
- 230000004069 differentiation Effects 0.000 abstract description 7
- 230000032683 aging Effects 0.000 abstract description 6
- 230000001066 destructive effect Effects 0.000 abstract description 6
- 102000004856 Lectins Human genes 0.000 description 14
- 108090001090 Lectins Proteins 0.000 description 14
- 239000002523 lectin Substances 0.000 description 14
- 238000013135 deep learning Methods 0.000 description 10
- 238000007689 inspection Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 102000023732 binding proteins Human genes 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 5
- 238000002659 cell therapy Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 235000021310 complex sugar Nutrition 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000011033 desalting Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000010801 machine learning Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000001808 exosome Anatomy 0.000 description 2
- 230000008975 immunomodulatory function Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000000985 reactive dye Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
Images
Landscapes
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
本発明は、細胞の状態を非破壊的に検査する検査装置と解析方法に関する。本発明の検査、解析は、分化細胞、幹細胞など多能性細胞等の細胞種の分類及び解析に関する。また、本発明の検査、解析はする細胞の状態としては、老化と活性度、多能性、分化指向性、有効性などがある。 The present invention relates to an inspection device and an analysis method for non-destructively inspecting the state of cells. The examination and analysis of the present invention relate to the classification and analysis of cell types such as pluripotent cells such as differentiated cells and stem cells. In addition, the state of cells to be examined and analyzed by the present invention includes aging and activity, pluripotency, differentiation orientation, and effectiveness.
細胞の状態を非破壊的に検査する検査装置、解析方法に関しては従来から種々の検査装置、解析方法が知られている。 Various inspection devices and analysis methods have been conventionally known for non-destructive inspection devices and analysis methods for the state of cells.
特許文献1には、細胞や生体組織の遺伝子発現態様や、抗原抗体反応を解析する試料チップ解析装置及び解析方法に関して、蛍光物質の励起光や外乱光に影響されることなく試料に結合された被検試料に標識された蛍光物質からの発光を確実、かつ高精度に検出して被検試料の解析作業を効率化できる試料チップ解析装置及び解析方法が記載されている。 In Patent Document 1, the gene expression mode of cells and biological tissues, the sample chip analyzer for analyzing the antigen-antibody reaction, and the analysis method are bound to the sample without being affected by the excitation light or the disturbance light of the fluorescent substance. A sample chip analyzer and an analysis method capable of reliably and highly accurately detecting light emission from a fluorescent substance labeled on a test sample to streamline the analysis work of the test sample are described.
特許文献2には、レクチンアレイの実用化に道を開く、タンパク質と糖鎖との相互作用を分析する方法が提案されている。レクチン、糖結合ドメインを有する酵素タンパク質、糖鎖に親和性を有するサイトカイン、または糖鎖に相互作用を示す抗体など、糖鎖に相互作用を示すタンパク質を固定化した基板に蛍光標識した被検糖鎖または被検複合糖質を接触させ、前記基板を洗浄せず、励起光(エバネッセント波)を作用させ、励起される蛍光の強度を測定することで、タンパク質と糖鎖との相互作用を分析する方法が記載されている。 Patent Document 2 proposes a method for analyzing the interaction between a protein and a sugar chain, which opens the way to the practical use of a lectin array. A test sugar fluorescently labeled on a substrate on which a protein that interacts with a sugar chain, such as a lectin, an enzyme protein having a sugar-binding domain, a cytokine having an affinity for a sugar chain, or an antibody that interacts with a sugar chain, is immobilized. The interaction between the protein and the sugar chain is analyzed by contacting the chain or the test complex sugar, not washing the substrate, allowing excitation light (evanescent wave) to act, and measuring the intensity of the excited fluorescence. How to do it is described.
特許文献3には、IgMクラスに属する糖鎖認識抗体やレクチンなどの糖鎖結合性タンパク質を複数種配置固定した導光性材料からなる基板と、該基板の側部端面に光を導入し、該基板表面にエバネッセント波を発生させて蛍光標識を励起する手段と、該手段により生じた蛍光の強度を上記糖鎖結合性タンパク質の配置位置毎に測定する蛍光強度測定手段とを有する、糖鎖あるいは複合糖質の解析装置が記載されている。 In Patent Document 3, light is introduced into a substrate made of a light-guiding material in which a plurality of sugar chain-binding proteins such as a sugar chain recognition antibody and a lectin belonging to the IgM class are arranged and fixed, and a side end surface of the substrate. A sugar chain having a means for generating an evanescent wave on the surface of the substrate to excite a fluorescent label and a means for measuring the fluorescence intensity for measuring the intensity of fluorescence generated by the means at each position of the sugar chain-binding protein. Alternatively, a complex sugar analyzer is described.
一方、品質管理項目としての間葉系幹細胞の必要最低評価条件としては、次の3項目が規定されている(非特許文献1)。
1.プラスティックへ接着し培養可能であること
2.細胞表面マーカーの発現について、CD73, CD90, CD105が陽性、CD45, CD34, CD14 or CD11b, CD79a or CD19, HLA-DRが陰性であること
3.骨芽細胞、脂肪細胞、軟骨細胞への分化能を有すること
On the other hand, the following three items are defined as the minimum necessary evaluation conditions for mesenchymal stem cells as quality control items (Non-Patent Document 1).
1. 1. Must be able to adhere to plastic and be cultured. Regarding the expression of cell surface markers, CD73, CD90, CD105 are positive, and CD45, CD34, CD14 or CD11b, CD79a or CD19, HLA-DR are negative. Has the ability to differentiate into osteoblasts, adipocytes, and chondrocytes
しかしながら、分化能試験は試験実施に非常に時間を要する。また、細胞表面マーカーの試験はフローサイトメーターで実施ができるため比較的容易であるが、これらのマーカーの特異性は高いとは言えず、識別可能な細胞に限界があることが指摘されている。具体的には、間葉系幹細胞と繊維芽細胞の判別は困難を極める(非特許文献2)。 However, the potency test takes a very long time to carry out. In addition, although the test of cell surface markers can be performed with a flow cytometer, it is relatively easy, but the specificity of these markers is not high, and it has been pointed out that there is a limit to the cells that can be identified. .. Specifically, it is extremely difficult to distinguish between mesenchymal stem cells and fibroblasts (Non-Patent Document 2).
また、国際細胞治療学会が推奨する間葉系幹細胞製剤の評価方法には、免疫調整機能の評価があり、IFNγ、TNFαらのサイトカイン刺激と遺伝子発現解析が推奨されている(非特許文献3)。 In addition, the evaluation method for mesenchymal stem cell preparations recommended by the International Cell Therapy Association includes evaluation of immunomodulatory function, and cytokine stimulation of IFNγ, TNFα, etc. and gene expression analysis are recommended (Non-Patent Document 3). ..
これは、間葉系幹細胞の抗炎症作用は、サイトカイン刺激によりどのような因子がどの位誘導されるかである程度予測可能とされており、間葉系幹細胞を用いた再生医療等製品において、その有効性に結び付くものと考えられているからである(非特許文献4)。 It is said that the anti-inflammatory effect of mesenchymal stem cells can be predicted to some extent by what factors are induced by cytokine stimulation and how much, and in products such as regenerative medicine using mesenchymal stem cells. This is because it is considered to be linked to effectiveness (Non-Patent Document 4).
免疫調整機能評価においても、サイトカイン刺激及び細胞のさらなる培養行う事が必要であるため試験時間を要し、試験のコスト増を伴うことが課題として指摘されている。なお、本評価は核酸抽出が必要であるため、細胞の破壊を行うこととなる。培養上清からエクソソームを回収して糖鎖プロファイリングを行う方法が知られているが(非特許文献5)、エクソソームの回収には超遠心を用いた濃縮作業が必要であり、簡便性高い方法とは言えない。 It has been pointed out that the evaluation of immunomodulatory function also requires a long test time because it requires cytokine stimulation and further culture of cells, which increases the cost of the test. Since this evaluation requires nucleic acid extraction, cells will be destroyed. A method of recovering exosomes from a culture supernatant and performing sugar chain profiling is known (Non-Patent Document 5), but recovery of exosomes requires a concentration operation using an ultracentrifugation, which is a highly convenient method. I can't say.
従って、間葉系幹細胞を用いた再生医療等製品の開発において、その「品質管理」方法には、時間や費用等の面で改善の余地が残されている。 Therefore, in the development of products such as regenerative medicine using mesenchymal stem cells, there is room for improvement in terms of time, cost, etc. in the "quality control" method.
本発明は、分化細胞、間葉系幹細胞など多能性細胞等の細胞種等を非破壊的に検査及び解析する方法を提供することを目的とする。また、本発明は細胞の状態、例えば、老化、活性度、多能性、分化指向性、有効性等を非破壊的に検査及び解析する方法を提供することを目的とする。 An object of the present invention is to provide a method for nondestructively inspecting and analyzing cell types such as pluripotent cells such as differentiated cells and mesenchymal stem cells. Another object of the present invention is to provide a method for nondestructively examining and analyzing a cell state, for example, aging, activity, pluripotency, differentiation orientation, efficacy and the like.
本発明者らは上記課題を解決すべく鋭意検討した結果、糖鎖結合性タンパク質を固定化したマイクロアレイを用いて、細胞から分泌される機能因子からその糖鎖プロファイルを取得して解析することにより、細胞を破壊することなく細胞種もしくは細胞状態を解析することができることを見出した。本発明はこれらの知見に基づいて完成されたものである。すなわち、上記課題を解決するためになされた発明は、以下の通りである。 As a result of diligent studies to solve the above problems, the present inventors obtained and analyzed the sugar chain profile from functional factors secreted from cells using a microarray on which a sugar chain-binding protein was immobilized. , Found that it is possible to analyze cell type or cell state without destroying cells. The present invention has been completed based on these findings. That is, the inventions made to solve the above problems are as follows.
[1]
糖鎖結合性タンパク質を固定化したマイクロアレイを用いて、培地中に細胞から分泌される機能因子からその糖鎖プロファイルを取得し、解析する方法。
[1]
A method of obtaining and analyzing a sugar chain profile from a functional factor secreted from cells in a medium using a microarray on which a sugar chain-binding protein is immobilized.
[2]
前記細胞がヒト細胞である[1]の解析方法。
[2]
The method for analyzing [1], wherein the cell is a human cell.
[3]
糖鎖プロファイルを取得する工程がエバネッセント波蛍光励起装置を用いて行われる[1]又は[2]の解析方法。
[3]
The analysis method of [1] or [2], wherein the step of acquiring the sugar chain profile is performed using an evanescent wave fluorescence excitation device.
[4]
前記培地が無血清培地である[1]乃至[3]のいずれかの解析方法。
[4]
The analysis method according to any one of [1] to [3], wherein the medium is a serum-free medium.
[5]
前記機能因子が糖タンパク質である[1]乃至[4]のいずれかの解析方法。
[5]
The analysis method according to any one of [1] to [4], wherein the functional factor is a glycoprotein.
本発明によれば、分化細胞、間葉系幹細胞など多能性細胞等の細胞種を非破壊的に検査及び解析方法を提供することができる。また、本発明は細胞の状態、例えば、老化、活性度、多能性、分化指向性、有効性等を非破壊的に検査及び解析方法を提供することができる。本発明の検査及び解析方法では、一切の前処理を行なわず検査及び解析することができるため、細胞を用いた再生医療等製品の開発において、品質管理にかかる時間の短縮や費用の軽減をすることができる。 According to the present invention, it is possible to provide a method for non-destructively examining and analyzing cell types such as pluripotent cells such as differentiated cells and mesenchymal stem cells. The present invention can also provide a non-destructive method for examining and analyzing cell states such as aging, activity, pluripotency, differentiation orientation, efficacy and the like. Since the inspection and analysis method of the present invention can be inspected and analyzed without performing any pretreatment, the time required for quality control and the cost can be reduced in the development of products such as regenerative medicine using cells. be able to.
以下に、本発明の解析方法について詳細に説明する。 The analysis method of the present invention will be described in detail below.
本発明の検査及び解析方法は、細胞培養の培地中に分泌される糖タンパク質のレクチンマイクロアレイを用いた糖鎖プロファイリングを用いることで、細胞の持つ特徴を非破壊的に解析するものである。 The test and analysis method of the present invention is to non-destructively analyze the characteristics of cells by using sugar chain profiling using a lectin microarray of glycoproteins secreted into a cell culture medium.
「細胞の持つ特徴を非破壊的に解析する」とは、細胞を破壊することなく細胞種もしくは細胞状態を解析するものである。 "Non-destructive analysis of cell characteristics" is to analyze cell type or cell state without destroying cells.
本発明の検査及び解析方法によれば、検査対象となる細胞を用いることなく、本来培地交換等で廃棄する培地を用いることで、低コストで細胞の持つ特徴を解析することができる。 According to the inspection and analysis method of the present invention, the characteristics of cells can be analyzed at low cost by using a medium that is originally discarded by medium replacement or the like without using the cells to be inspected.
本発明の検査及び解析方法では、細胞の状態を、糖鎖結合性タンパク質を固定化したマイクロアレイを用いて、培地中に分泌される機能因子からその糖鎖プロファイルを取得し、非破壊的に解析する。 In the test and analysis method of the present invention, the state of cells is analyzed non-destructively by obtaining the sugar chain profile from the functional factors secreted in the medium using a microarray on which a sugar chain-binding protein is immobilized. To do.
本発明の解析方法において、糖鎖プロファイルを取得する工程は、エバネッセント波蛍光励起装置を用いて行うことができる。 In the analysis method of the present invention, the step of acquiring the sugar chain profile can be performed using an evanescent wave fluorescence excitation device.
エバネッセント波蛍光励起装置とは、糖鎖結合性タンパク質が固定化されたマイクロアレイの表面にエバネッセント波(近接場)を発生させ、解析対象になっている前記細胞から前記培地中に分泌される機能因子と、前記糖鎖結合性タンパク質との相互作用を、前記マイクロアレイ表面の洗浄や乾燥操作を行わず、非破壊で検出できる装置である。 The evanescent wave fluorescence exciter is a functional factor that generates an evanescent wave (proximity field) on the surface of a microarray on which a sugar chain-binding protein is immobilized and is secreted into the medium from the cell to be analyzed. It is a device that can detect the interaction with the sugar chain-binding protein in a non-destructive manner without washing or drying the surface of the microarray.
エバネッセント波蛍光励起装置としては、株式会社グライコテクニカのGlycoStation ReaderやGlycoLite等が例示される。 Examples of the evanescent wave fluorescence excitation device include Glyco Station Reader and Glyco Lite of Glyco Technica Co., Ltd.
本発明において、検査及び解析を行う細胞は、本発明の効果が得られる限り特に限定されるものではないが、例えば、ヒト細胞が挙げられる。本発明において、検査及び解析を行う細胞種としては、本発明の効果が得られる限り特に限定されるものではないが、例えば、分化細胞、間葉系幹細胞などの多能性細胞が挙げられる。 In the present invention, the cells to be examined and analyzed are not particularly limited as long as the effects of the present invention can be obtained, and examples thereof include human cells. In the present invention, the cell type to be examined and analyzed is not particularly limited as long as the effects of the present invention can be obtained, and examples thereof include pluripotent cells such as differentiated cells and mesenchymal stem cells.
本発明において、検査及び解析する細胞の状態としては、本発明の効果が得られる限り特に限定されるものではないが、例えば、老化と活性度、多能性、分化指向性、有効性が挙げられる。 In the present invention, the state of the cell to be examined and analyzed is not particularly limited as long as the effect of the present invention can be obtained, and examples thereof include aging and activity, pluripotency, differentiation orientation, and effectiveness. Be done.
本発明で用いる培地は細胞を培養できる培地であれば、特に限定されないが、例えば、無血清培地が挙げられる。 The medium used in the present invention is not particularly limited as long as it is a medium capable of culturing cells, and examples thereof include a serum-free medium.
本発明で用いる機能因子は、本発明の効果が得られる限り特に限定されるものではないが、糖タンパク質が挙げられる。 The functional factors used in the present invention are not particularly limited as long as the effects of the present invention can be obtained, and examples thereof include glycoproteins.
無血清培地とは、血清を含まない動物細胞培養用の培地であり、動物細胞を人工的に培養する場合に、必要な増殖因子等の成分を補うため、培地中に5〜20%程度の血清を添加した培地に対比して、血清を添加せずに同様な効果を実現したものである。 The serum-free medium is a medium for culturing animal cells that does not contain serum, and is about 5 to 20% in the medium in order to supplement components such as growth factors necessary for artificially culturing animal cells. Compared with the medium to which serum was added, the same effect was realized without adding serum.
本発明において、解析には機械学習の中でも特に教師あり学習を使用することができる。「教師あり学習」とは、ソフトウェアに目的の結果を導き出す手順をハードコーディングすることなく、データから反復的に学習し、そこに潜むパターンから独自の手順を見つけ出す学習方法である。 In the present invention, supervised learning can be used for analysis, among other machine learning. "Supervised learning" is a learning method that iteratively learns from data and finds a unique procedure from the patterns hidden in it, without hard-coding the procedure to derive the desired result in software.
本発明の解析方法の機械学習として、深層学習(ディープラーニング)を使用することができる。「深層学習」とは、神経細胞間の情報伝達を参考にしたニューラルネットワークを何層も重ねることにより、データの学習をへて分析を行う教師あり学習の一手法である。 Deep learning can be used as machine learning for the analysis method of the present invention. "Deep learning" is a supervised learning method that analyzes data through the learning of data by stacking multiple layers of neural networks that refer to information transmission between nerve cells.
本発明の検査及び解析方法には糖鎖との弱い結合を漏れなく検出するためのエバネッセント波蛍光励起スキャナー、試料チップ解析装置、糖鎖プロファイルを取得するためのエバネッセント波蛍光励起装置を用いることができる。 The inspection and analysis method of the present invention may use an evanescent wave fluorescence excitation scanner for detecting weak bonds with sugar chains without omission, a sample chip analyzer, and an evanescent wave fluorescence excitation device for acquiring a sugar chain profile. it can.
本発明の検査及び解析方法には特許文献1、2、3に記載されたタンパク質と糖鎖との相互作用を分析する方法を用いることができる。本発明の検査及び解析方法には特許文献1、2、3に記載された糖鎖あるいは複合糖質の解析装置を用いることができる。本発明の検査及び解析方法にはその他の従来技術を使用することができる。 As the inspection and analysis method of the present invention, the method for analyzing the interaction between a protein and a sugar chain described in Patent Documents 1, 2 and 3 can be used. As the inspection and analysis method of the present invention, the sugar chain or complex sugar analyzer described in Patent Documents 1, 2 and 3 can be used. Other prior art techniques can be used for the inspection and analysis methods of the present invention.
以下、本発明の実施例を説明するが、本発明は上述した実施の形態、以下の実施例に限られるものではなく、特許請求の範囲の記載から把握される技術的範囲において種々に変更可能である。 Hereinafter, examples of the present invention will be described, but the present invention is not limited to the above-described embodiments and the following examples, and can be variously changed within the technical scope grasped from the description of the claims. Is.
ヒト脂肪組織由来間葉系幹細胞(以下「AD」と言う)、ヒト臍帯由来間葉系幹細胞(以下「UC」と言う)、ヒト肺線維芽細胞(以下「Lung」と言う)、ヒト肝由来線維芽細胞(以下「Liver」と言う)、ヒト動脈由来細胞(以下「Aorta」と言う)を間葉系幹細胞用無血清培地(ロート製薬製)で培養した。 Human adipose tissue-derived mesenchymal stem cells (hereinafter referred to as "AD"), human umbilical band-derived mesenchymal stem cells (hereinafter referred to as "UC"), human lung fibroblasts (hereinafter referred to as "Lung"), human liver-derived Fibroblasts (hereinafter referred to as "Liver") and human artery-derived cells (hereinafter referred to as "Aorta") were cultured in a serum-free medium for mesenchymal stem cells (manufactured by Rohto Pharmaceutical Co., Ltd.).
培養後2日及び4日において20μLの培養上清を回収し、下記のプロトコルに従って試料の前処理を行った。 20 μL of the culture supernatant was collected 2 and 4 days after the culture, and the sample was pretreated according to the following protocol.
1.各試料20μLとCy3 Mono-Reactive dye 100μg labeling(GE Healthcare, PA23001を100μg labelingずつ子分けたもの)を混合し、室温、暗所で1時間反応させた。 1. 1. 20 μL of each sample and 100 μg labeling of Cy3 Mono-Reactive dye (GE Healthcare, PA23001 divided into 100 μg labeling) were mixed and reacted at room temperature in the dark for 1 hour.
2.脱塩カラム(Zeba(商標)Spin Desalting Columns, 7K MWCO (Thermo SCIENTIFIC, 89882)を1,500×g、1分間、4℃で遠心した。 2. 2. Desalted columns (Zeba ™ Spin Desalting Columns, 7K MWCO (Thermo SCIENTIFIC, 89882)) were centrifuged at 1,500 xg for 1 minute at 4 ° C.
3.脱塩カラムにTBS=300μLをアプライし、1,500×g、1分間、4℃で遠心する (カラム洗浄) 。この工程を2回繰り返した。 3. 3. Apply TBS = 300 μL to the desalting column and centrifuge at 1,500 × g for 1 minute at 4 ° C (column wash). This process was repeated twice.
4.脱塩カラムに各試料全量とT= 25μLをアプライして、1,500×g、2分間、4℃で遠心し、未反応のCy3を除いた。 4. The whole amount of each sample and T = 25 μL were applied to a desalting column and centrifuged at 1,500 × g for 2 minutes at 4 ° C. to remove unreacted Cy3.
5.各試料にProbing Solution 450μLをアプライし、500μL/tubeにメスアップした。 5. Probing Solution 450 μL was applied to each sample, and the sample was increased to 500 μL / tube.
6.LecChip(登録商標)(GlycoTechnica製レクチンマイクロアレイ)をProbing Solution(100μL/ウェル)(GlycoTechnica製 LecChip用プロービング液)で3回洗浄後、各試料(100μL/ウェル)をアプライし、LecChip(登録商標)を20℃で、17時間以上反応させた。 6. After washing LecChip (registered trademark) (GlycoTechnica lectin microarray) with Probing Solution (100 μL / well) (GlycoTechnica probing solution for LecChip) three times, apply each sample (100 μL / well) and apply LecChip (registered trademark). The reaction was carried out at 20 ° C. for 17 hours or more.
7.試料を反応させたままの液相状態のLecChip(登録商標)をGlycoStation(登録商標)Reader 1200 (GlycoTechnica製 エバネッセント波蛍光励起スキャナー)で測定した(測定条件,積算回数: 4回、露光時間: 133msec、カメラゲイン: 75, 85, 95, 105, 115, 125)。 7. LecChip (registered trademark) in the liquid phase state in which the sample was reacted was measured with GlycoStation (registered trademark) Reader 1200 (Evanescent wave fluorescence excitation scanner manufactured by GlycoTechnica) (measurement conditions, number of integrations: 4, exposure time: 133 msec) , Camera gain: 75, 85, 95, 105, 115, 125).
8.GlycoStaion(登録商標)Tools Pro Suite 1.5 (GlycoTechnica製 糖鎖解析ソフトウェア)による数値化、データ統合(ゲイン統合) を行った。 8. Quantification and data integration (gain integration) were performed using GlycoStaion (registered trademark) Tools Pro Suite 1.5 (GlycoTechnica sugar chain analysis software).
9.データ統合(ゲイン統合)した数値データについて、すべての数値化データをMicrosoft(登録商標) Excelのシートにエキスポートした。なお、表計算ソフトウェアのスプレッドシートにエキスポートしてもよい。 9. For the numerical data that was data-integrated (gain-integrated), all the digitized data was exported to the Microsoft (registered trademark) Excel sheet. It may be exported to a spreadsheet of spreadsheet software.
以上のように前処理を行った試料について、45種類のレクチンが搭載されたレクチンマイクロアレイ(LecChip(登録商標))を用いて糖鎖プロファイラー(GlycoStation(登録商標)Reader 1200)でスキャンして得られる蛍光強度(糖鎖プロファイル)に基づく糖鎖プロファイリングを行った。その結果の比較図を図1に示した。図1中、Beforeは、細胞を培養していない培地であり、Afterは、細胞培養後2日の培地中の糖鎖プロファイリングを示した。 It is obtained by scanning the pretreated sample as described above with a sugar chain profiler (GlycoStation (registered trademark) Reader 1200) using a lectin microarray (LecChip (registered trademark)) equipped with 45 types of lectins. Sugar chain profiling based on the fluorescence intensity (sugar chain profile) was performed. A comparative diagram of the results is shown in FIG. In FIG. 1, Before is a medium in which cells are not cultured, and After is sugar chain profiling in the medium 2 days after cell culture.
細胞を培養していない培地の上清からは、STL、 UDA以外の信号は検出されず、細胞培養後2日の培地の上清からは数多くのレクチンの信号が検出された。また、図としては示していないが、細胞培養後4日の培地の上清からは、細胞培養後2日の培地の上清に比べて検出されるレクチンの信号が増加しており、細胞培養後に見られる数多くのレクチンからの信号は、培地中に細胞から分泌された因子であることが確認された。 No signals other than STL and UDA were detected in the supernatant of the medium in which the cells were not cultured, and many lectin signals were detected in the supernatant of the medium 2 days after the cell culture. In addition, although not shown in the figure, the signal of lectin detected from the supernatant of the medium 4 days after the cell culture is increased as compared with the supernatant of the medium 2 days after the cell culture, and the cell culture It was confirmed that the signals from many lectins seen later were factors secreted from cells in the medium.
図1に示されるような45種類のレクチンが搭載されたレクチンマイクロアレイ(LecChip(登録商標))を用いて糖鎖プロファイラー(GlycoStation(登録商標)Reader 1200)でスキャンして得られる蛍光強度(糖鎖プロファイル)から、教師なし学習および教師あり学習の両方に共通して用いるための45要素からなる特徴ベクトルを作成した。 Fluorescence intensity (sugar chain) obtained by scanning with a sugar chain profiler (GlycoStation (registered trademark) Reader 1200) using a lectin microarray (LecChip (registered trademark)) equipped with 45 types of lectins as shown in FIG. From the profile), a feature vector consisting of 45 elements was created for common use in both unsupervised learning and supervised learning.
蛍光強度に1.0を足して常用対数を取ることで、小さな蛍光強度の差を強調し、大きな蛍光強度の差を縮小させた上で、その最小値を0に、最大値が1になるように正規化を行った。 By adding 1.0 to the fluorescence intensity and taking the common logarithm, the difference in small fluorescence intensity is emphasized, the difference in large fluorescence intensity is reduced, and the minimum value is set to 0 and the maximum value is set to 1. Normalization was done as follows.
正規化法(x:測定された蛍光強度、xmin:測定された最小蛍光強度、xmax:測定された最大蛍光強度、y:規格化後)
y = (log(x + 1.0) - log(xmin + 1.0)) / (log(xmax + 1.0) - log(xmin + 1.0))
Normalization method (x: measured fluorescence intensity, x min : measured minimum fluorescence intensity, x max : measured maximum fluorescence intensity, y: after normalization)
y = (log (x + 1.0) --log (x min + 1.0)) / (log (x max + 1.0) --log (x min + 1.0))
教師あり学習は、オンライン機械学習向け分散処理フレームワークJubatus (http://jubat.us/) に含まれる多値分類機能Classifierを利用して線形分類、さらに深層学習に対応したフレームワーク TensorFlow (http://tensorflow.org/) およびそのインターフェースであるKeras (http://keras.io/) を利用して深層学習を行った。 Supervised learning is a framework that supports linear classification and deep learning using the multi-value classification function Classifier included in the distributed processing framework Jubatus (http://jubat.us/) for online machine learning. TensorFlow (http) Deep learning was performed using //tensorflow.org/) and its interface Keras (http://keras.io/).
これらにおけるハイパーパラメータの最適化には、サンプル数が多くないため、一個抜き交差検証により行った。サンプル数の数だけ分類機の認識精度を出力し、最終的な認識精度を高めるための設定変更を重ねた。 Since the number of samples is not large, the optimization of hyperparameters in these was performed by cross-validation without one. The recognition accuracy of the classifier was output as many as the number of samples, and the settings were changed repeatedly to improve the final recognition accuracy.
線形分類では深層学習ほどの認識精度を望むことができないが、各レクチンの蛍光強度がどの程度分類に寄与したかを知ることができるため、この目的で利用した。認識精度を最大限高めるためにClassifierで利用するAROW等アルゴリズムの選択を行い、さらにそれらのアルゴリズムで設定可能なregularization weight値等の最適化を行った。完成させた線形分類機から、それぞれの分類に寄与したレクチンのランキングを作成し、後述する深層学習で得られた結果を補完するために用いた。 Although linear classification cannot be expected to have the same recognition accuracy as deep learning, it was used for this purpose because it is possible to know how much the fluorescence intensity of each lectin contributed to the classification. In order to maximize the recognition accuracy, we selected algorithms such as AROW to be used in the Classifier, and further optimized the regularization weight value that can be set by those algorithms. From the completed linear classifier, a ranking of lectins that contributed to each classification was created and used to complement the results obtained in deep learning described later.
深層学習は、affine層(全結合層)による隠れ層の積み重ねで構成した。活性化関数はReLU関数、重みの初期値はHeの初期値を用いた。2分類の場合、出力層の出力は単一ノードのSigmoid関数を用い、0に近いか1に近いかにより2分類を行うことができる。3分類以上の場合は、出力層のノード数を分類数に合わせることにより分類することができる。隠れ層の数は2から7程度、各層におけるノード数は4から60程度、batchサイズ、batch normalizationの利用、dropoutの値、学習率、SGD以外のパラメータ更新法の検討などのハイパーパラメータ最適化を行った。 Deep learning consisted of stacking hidden layers by affine layers (fully connected layers). The ReLU function was used as the activation function, and the initial value of He was used as the initial value of the weight. In the case of two classifications, the output of the output layer can be classified into two categories according to whether it is close to 0 or 1 by using the Sigmoid function of a single node. In the case of 3 or more classifications, the number of nodes in the output layer can be classified according to the number of classifications. The number of hidden layers is about 2 to 7, the number of nodes in each layer is about 4 to 60, and hyperparameter optimization such as batch size, use of batch normalization, dropout value, learning rate, and examination of parameter update methods other than SGD. went.
具体的には、図2に示すような入力層から出力層に至る構成で深層学習を行った。 Specifically, deep learning was performed with a configuration from the input layer to the output layer as shown in FIG.
深層学習による細胞種の認識精度は、表1に示す如くとなった。用いているサンプル数は、AD=105、UC=30、Lung=6、Liver=6、Aorta=6サンプルである。
表1から、間葉系幹細胞(AD、UD)が90%を超える精度で認識されており、品質確認の基礎となる細胞種の判定において有意な性能が得られていることがわかった。この結果は、対象となる細胞は非破壊にて、従来捨てられていた培地から特段の前処理なしに得られた結果であることを強調するものである。 From Table 1, it was found that mesenchymal stem cells (AD, UD) were recognized with an accuracy of more than 90%, and significant performance was obtained in determining the cell type that is the basis of quality confirmation. This result emphasizes that the cells of interest were non-destructive and were obtained from a previously discarded medium without any special pretreatment.
本発明により、分化細胞、間葉系幹細胞など多能性細胞等の細胞種等を非破壊的に検査及び解析する方法を提供する。また、本発明により細胞の状態、例えば、老化、活性度、多能性、分化指向性、有効性等を非破壊的に検査及び解析する方法を提供する。 INDUSTRIAL APPLICABILITY The present invention provides a method for nondestructively inspecting and analyzing cell types such as pluripotent cells such as differentiated cells and mesenchymal stem cells. The present invention also provides a method for non-destructively examining and analyzing cell states such as aging, activity, pluripotency, differentiation orientation, efficacy and the like.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019024097A JP7369393B2 (en) | 2019-02-14 | 2019-02-14 | Non-destructive cell analysis method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019024097A JP7369393B2 (en) | 2019-02-14 | 2019-02-14 | Non-destructive cell analysis method |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020134179A true JP2020134179A (en) | 2020-08-31 |
JP7369393B2 JP7369393B2 (en) | 2023-10-26 |
Family
ID=72278380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019024097A Active JP7369393B2 (en) | 2019-02-14 | 2019-02-14 | Non-destructive cell analysis method |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7369393B2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009148236A (en) * | 2007-12-20 | 2009-07-09 | Glycoresearch Kk | Method for identifying fibroblast |
US20120282628A1 (en) * | 2011-05-06 | 2012-11-08 | Korea Basic Science Institute | Method for diagnosing cancer using lectin |
JP2017184713A (en) * | 2016-03-31 | 2017-10-12 | 国立研究開発法人産業技術総合研究所 | Method for determining cell differentiation potential |
-
2019
- 2019-02-14 JP JP2019024097A patent/JP7369393B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009148236A (en) * | 2007-12-20 | 2009-07-09 | Glycoresearch Kk | Method for identifying fibroblast |
US20120282628A1 (en) * | 2011-05-06 | 2012-11-08 | Korea Basic Science Institute | Method for diagnosing cancer using lectin |
JP2017184713A (en) * | 2016-03-31 | 2017-10-12 | 国立研究開発法人産業技術総合研究所 | Method for determining cell differentiation potential |
Non-Patent Citations (1)
Title |
---|
SHIMODA, A. ET AL.: "Glycan profiling analysis using evanescent-field fluorescence-assisted lectin array: Importance of s", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 491, JPN6022041999, 2017, pages 701 - 707, XP085181371, ISSN: 0005026553, DOI: 10.1016/j.bbrc.2017.07.126 * |
Also Published As
Publication number | Publication date |
---|---|
JP7369393B2 (en) | 2023-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Srivastava et al. | Biosensor-based detection of tuberculosis | |
Cooper et al. | Direct and sensitive detection of a human virus by rupture event scanning | |
Bhalla et al. | Nanoplasmonic biosensor for rapid detection of multiple viral variants in human serum | |
Sezgintürk | A new impedimetric biosensor utilizing vegf receptor-1 (flt-1): Early diagnosis of vascular endothelial growth factor in breast cancer | |
Robinson et al. | Flow cytometry: the next revolution | |
Liébana et al. | Electrochemical immunosensors, genosensors and phagosensors for Salmonella detection | |
Joung et al. | Ultra-sensitive detection of pathogenic microorganism using surface-engineered impedimetric immunosensor | |
Maglio et al. | A quartz crystal microbalance immunosensor for stem cell selection and extraction | |
Wang et al. | Immunophenotyping of acute leukemia using an integrated piezoelectric immunosensor array | |
Spadafora et al. | Species-specific immunodetection of an Entamoeba histolytica cyst wall protein | |
Tran et al. | Simple Label‐Free Electrochemical Immunosensor in a Microchamber for Detecting Newcastle Disease Virus | |
Bigdeli et al. | Electrochemical impedance spectroscopy (EIS) for biosensing | |
Lee et al. | Automated estimation of cancer cell deformability with machine learning and acoustic trapping | |
Andryukov et al. | Raman spectroscopy as a modern diagnostic technology for study and indication of infectious agents | |
Moreira et al. | Development of a Biosensor Based on Angiotensin‐Converting Enzyme II for Severe Acute Respiratory Syndrome Coronavirus 2 Detection in Human Saliva | |
US20220120745A1 (en) | Cell-free biofragment compositions and related systems, devices, and methods | |
JP2003000223A (en) | Microorganism determination apparatus, electrode chip for microorganism determination by the apparatus and microorganism determination method | |
Li et al. | Edge-enhanced microwell immunoassay for highly sensitive protein detection | |
JP7369393B2 (en) | Non-destructive cell analysis method | |
Béland et al. | Viability assessment of bacteria using long-range surface plasmon waveguide biosensors | |
CN102099494A (en) | Method and system for detecting and/or quantifying bacteriophages, use of a microelectronic sensor device for detecting said bacteriophages and microelectronic sensor device for implementing said method | |
Quang Thinh et al. | A label-free electrochemical immunosensor for detection of Newcastle disease virus | |
JP7481758B2 (en) | Method for detecting a target substance in a sample | |
Al-Ghobashy et al. | Coupled solid phase extraction and microparticle-based stability and purity-indicating immunosensor for the determination of recombinant human myelin basic protein in transgenic milk | |
EP3951022A1 (en) | Process for modifying the surface of electrodes for the construction of electrochemical biosensors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190227 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211111 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220930 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221004 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20221101 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20221101 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221202 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230123 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230118 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230404 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230602 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230728 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230905 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231005 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7369393 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |